BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24

• Press Releases

  NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

  August 17, 2026

   · 

  11 min read
• Press Releases

  EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

  August 17, 2026

   · 

  17 min read
• Press Releases

  Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer

  August 17, 2026

   · 

  6 min read
• Press Releases

  InspireMD Reports Second Quarter 2026 Financial Results

  August 17, 2026

   · 

  18 min read
• Castle Biosciences Approved for Dual Listing on Nasdaq Texas

  August 17, 2026

   · 

  5 min read
• Press Releases

  Kelun-Biotech Announces 2026 Interim Results

  August 17, 2026

   · 

  10 min read
• Press Releases

  United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

  August 17, 2026

   · 

  10 min read
• Press Releases

  TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO

  August 17, 2026

   · 

  18 min read
• Press Releases

  Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

  August 17, 2026

   · 

  4 min read
• 

  Lung cancer

  AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow

  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.

  August 17, 2026

   · 

  2 min read

   · 

  Tristan Manalac